Johnson & Johnson today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit ...
BioMarin Pharmaceutical Inc. today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically significant lowering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback